+

WO2003103593A3 - Secretases associees a la maladie d'alzheimer - Google Patents

Secretases associees a la maladie d'alzheimer Download PDF

Info

Publication number
WO2003103593A3
WO2003103593A3 PCT/US2003/017896 US0317896W WO03103593A3 WO 2003103593 A3 WO2003103593 A3 WO 2003103593A3 US 0317896 W US0317896 W US 0317896W WO 03103593 A3 WO03103593 A3 WO 03103593A3
Authority
WO
WIPO (PCT)
Prior art keywords
secretases
dementia
alzheimer
secretase
methods
Prior art date
Application number
PCT/US2003/017896
Other languages
English (en)
Other versions
WO2003103593A2 (fr
Inventor
Vivian Y H Hook
Original Assignee
Buck Inst
Vivian Y H Hook
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Buck Inst, Vivian Y H Hook filed Critical Buck Inst
Priority to AU2003248635A priority Critical patent/AU2003248635A1/en
Publication of WO2003103593A2 publication Critical patent/WO2003103593A2/fr
Publication of WO2003103593A3 publication Critical patent/WO2003103593A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Food Science & Technology (AREA)
  • Neurology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention porte sur une méthode de détermination de l'activité protéolytique in vivo de secrétases, et en particulier de la B -secrétase et de la Y-secrétase, qui produit les peptides A B</i> trouvés dans les plaques de patients atteints de la maladie d'Alzheimer. L'invention porte également sur des méthodes d'isolement desdites secrétases et sur des méthodes de sélection d'agents influant sur l'activité desdites secrétases permettant de développer des médicaments pouvant traiter ladite maladie.
PCT/US2003/017896 2002-06-05 2003-06-05 Secretases associees a la maladie d'alzheimer WO2003103593A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003248635A AU2003248635A1 (en) 2002-06-05 2003-06-05 Secretases related to alzheimer's dementia

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38654002P 2002-06-05 2002-06-05
US60/386,540 2002-06-05

Publications (2)

Publication Number Publication Date
WO2003103593A2 WO2003103593A2 (fr) 2003-12-18
WO2003103593A3 true WO2003103593A3 (fr) 2005-07-07

Family

ID=29736174

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/017896 WO2003103593A2 (fr) 2002-06-05 2003-06-05 Secretases associees a la maladie d'alzheimer

Country Status (2)

Country Link
AU (1) AU2003248635A1 (fr)
WO (1) WO2003103593A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE523788T1 (de) * 2006-06-08 2011-09-15 Fu Berlin ASSAY ZUR DIAGNOSE VON ALZHEIMER BASIEREND AUF DER BESTIMMUNG DES VERHÄLTNISSES VON SEKRETASE-Aß-SPALTPRODUKTEN

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6313268B1 (en) * 1998-10-16 2001-11-06 Vivian Y. H. Hook Secretases related to Alzheimer's dementia

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6313268B1 (en) * 1998-10-16 2001-11-06 Vivian Y. H. Hook Secretases related to Alzheimer's dementia

Also Published As

Publication number Publication date
AU2003248635A1 (en) 2003-12-22
WO2003103593A2 (fr) 2003-12-18
AU2003248635A8 (en) 2003-12-22

Similar Documents

Publication Publication Date Title
IL280818A (en) Methods of production of alpha-galactosides preparations
GB0108592D0 (en) Therapeutic agents
WO2000023576A3 (fr) Secretases liees a la demence d&#39;alzheimer
GB0223040D0 (en) Therapeutic compounds
MY134906A (en) Prevention and treatment of amyloidogenic disease
ATE349446T1 (de) Amyloid plaque aggregationshemmer und diagnostische bilderzeugungsmittel
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
HK1087398A1 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
WO2000078344A8 (fr) Peptides proteiniques du prion et utilisations associees
SG147274A1 (en) Prevention and treatment of amyloidogenic disease
GB0117326D0 (en) Napthoquinone-type inhibitors of protein aggregation
SG149063A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
EP1068304A4 (fr) Traitement de maladies parasitaires par l&#39;inhibition des cysteine-proteases de la superfamille de la papaine
AU2002365365A1 (en) Metal complex compounds
ATE318328T1 (de) Diagnostika und therapeutika für osteoporose
DK1353948T3 (da) Oplöselige biologiske analoge til bata-amyloidpeptid
SI1553985T1 (sl) Bifenili kot sredstva za slikanje pri Alzheimerjevi bolezni
MXPA03010881A (es) Composiciones para retirar cerumen humado.
WO2003031585A3 (fr) Molecules d&#39;acide nucleique codant une serine protease transmembranaire 25, polypeptides codes et procedes connexes
WO2003103593A3 (fr) Secretases associees a la maladie d&#39;alzheimer
WO2004003563A3 (fr) Utilisation diagnostique et therapeutique de la proteine et du gene ensadin-0581 dans le cadre des maladies neurodegeneratives
IL171384A (en) Use of slurp-1 in the preparation of medicaments for the treatment of neurological disorders
WO2004038411A3 (fr) Utilisations diagnostique et therapeutique d&#39;un gene de l&#39;ensadin-0289 et d&#39;une proteine pour des maladies neurodegeneratives
BR0314541A (pt) Tratamento de demência e doença de parkinson
NZ514691A (en) Method to type prion proteins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载